CA 125 and CA 15.3 antigens were determined by enzyme immunoassay in 78 patients with ovarian cancer for a total of 540 determinations. The antigens were also investigated in sera from 100 women with other gynaecological diseases, 82 lung cancer patients and in 39 pleural fluids of varying origin. CA 15.3 reference values were evaluated in 91 healthy women (cut-off: 25 U/ml). CA 15.3 sensitivity at diagnosis (60%) and for detecting relapse (44%) was lower than that of CA 125 (90% and 64,7%, respectively). However, CA 15.3 does not increase with aspecific mesothelial cell reaction and thus it is more specific than CA 125. Combined use of the markers during follow-up improves early detection of relapse (at least one of the two was positive in 79%, of cases). Therefore both CA 15.3 and CA 125 should be routinely determined for the detection and monitoring of ovarian cancer.
PavesiF., LotznikerM., MarbelloL., GarbagnoliP., FranchiM., MorattiR.. Ca 125 in benign and malignant diseases involving coelomic epithelium.J Tumour Marker Oncology1988; 1: 49–57.
2.
HalilaH., StenmanU.H., SeppalaM.. Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy.Cancer1986; 57: 1327–29.
3.
MastropaoloW., FernandezZ., MillerE.L.. Pronounced increases in the concentration of an ovarian tumour marker, Ca 125, in serum of a healthy subject during menstruation.Clin Chem1986; 11: 2110–1.
4.
KangJ.O., HudakW.A., KellerN., CriswellB.S.. Enzyme-linked immunosorbent assay of Ca 125 in serum of patients with endometriosis: efficacy in diagnosis.Clin Chem1988; 10: 1983–6.
5.
ZurawskiV.R., BroderickS.F., PickensP., KnappR.C., BastR.C.. Serum Ca 125 levels in a group of non hospitalized women: relevance for the early detection of ovarian cancer.Obstet Gynecol1987; 4: 606–11.
6.
JacobsI.. Screening for early ovarian cancer.Lancet1988; 16: 171–2.
7.
YedemaC., MassugerL., HilgerJ.. Pre-operative discrimination between benign and malignant ovarian tumour using a combination of CA 125 and CA 15.3 serum assays.Int J Cancer1988; 3(suppl): 61–7.
8.
ZurawskiV.R., OrjaseterH., AndersenA., JellumE.. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer.Int J Cancer1988; 42: 6770–80.
9.
MeierW., StieberP., Fateh-MoghadamA., EiermannW., HeppH.. Ca 125 in gynecological malignancies.Eur J Cancer Clin Oncol1987; 6: 713–7.
10.
KhooS.K., HurstT., WebbM.J., DickieG.J., KearsleyJ.H., MackayE.V.. Predictive value of serial Ca 125 antigen levels in ovarian cancer evaluated by second-look laparotomy.Eur J Cancer Clin Oncol1987; 6: 765–71.
11.
MartoniA., BelluccoA., MarabibiA.., Ca 125 monitoring during chemotherapy for ovarian cancer.Int J Biol Markers1986; 3: 121–8.
12.
ScambiaG., Benedetti PaniciP., BaiocchiG.. Ca 15.3 serum levels in ovarian cancer.Oncology1988; 45: 263–7.
13.
FriedmanE.L., HayesD.F., KufeD.W.. Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas.Cancer Res1986; 46: 5189–94.
14.
DavisH.M., ZurawskiV.R., BastR.C., KlugTL. Characterization of the Ca 125 antigen associated with human epithelial ovarian carcinomas.Cancer Res1986; 46: 6143–8.
15.
SekineH., HayesD.F., OhnoT.. Circulating DF3 and Ca 125 antigen levels in serum from patients with epithelial ovarian carcinoma.J Clin Oncol1985; 10: 1355–63.
16.
HilkensJ., KroezenV., BonfrerJ.M.G., De Jong-BakkerM., BrunningP.F.. MAM-6 antigen, a new serum marker for breast cancer monitoring.Cancer Res1986; 46: 2582–7.
17.
HilkensJ., BuusF., HilgersJ.. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumours.Int J Cancer1984; 34: 197–206.
18.
MacDonaldF., BirdR., StokesH., RusselB., CrockerJ.. Expression of CEA, Ca 125, Ca 19-9 and human milk fat globule membrane antigen in ovarian tumours.J Clin Pathol1988; 41: 260–4.
19.
WardB.G., CruickshankD.J., TuckerD.F., LoveS.. Independent expression in serum of three tumour-associated antigens: Ca 125, placental alkaline phosphatase and HMFG2 in ovarian carcinoma.Br J Obstet Gynaecol1987; 94: 696–8.
20.
HilkensJ., BuijsF., LigtenbergM.. Complexity of MAM-6, an epithelial sialomucin associated with carcinomas.Cancer Res1989; 49: 786–93.
21.
PavesiF., LotznikerM., CremaschiP., MarbelloL., AcquistapaceL., MorattiR.. Detection of malignant pleural effusions by tumour marker evaluation.Eur J Cancer Clin Oncol1988; 24: 1005–11.
22.
ShimokadaK., TotaniY., NakanishiK.. Diagnostic value of cancer antigen 15-3 (Ca 15-3) detected by monoclonal antibodies (115D8 and DF3) in exudative pleural effusions.Eur Respir J1988; 1: 341–4.
23.
BrioschiP.A., IrionO., BischofP., BaderM., ForniM., KrauerF.. Serum Ca 125 in epithelial ovarian cancer. A longitudinal study.Br J Obstet Gynaecol1987; 94: 196–201.
24.
MobusV., KreienbergR., CrombachG.. Evaluation of Ca 125 as a prognostic and predictive factor in ovarian cancer.J Tumour Marker Oncology1988; 2: 251–8.
25.
Van der BurgM.E.L., LammesF.B., van PuttenW.L.J., StoterG.. Ovarian cancer: the prognostic value of the serum half-life of Ca 125 during induction chemotheraphy.Gynecol Oncol1988; 30: 307–12.
26.
EskelinenM., TikanojaS., ValkamoE., LoikkanenM., CollanY.. Cancer associated antigen Ca 15-3 in the diagnostics of breast tumours.Scand J Clin Lab Invest1988; 48: 653–8.
27.
PavesiF., LotznikerM., FranchiM., AntononiA., MorattiR.. CA 15.3 and CA 125 antigens in ovarian cancer surveillance (Abstract).J Tumour Marker Oncology1989; 4: 167.
